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ciation for Thoracic Surgerydoi:10.1016/j.jtcvs.2005.04.031Objectives: Hepatocyte growth factor plays a significant role in angiogenesis,
anti-apoptosis, and anti-transforming growth factor-1–mediated fibrosis in several
organs. In this study, we investigated the effect of transfection of the hepatocyte
growth factor gene in attenuation of cardiac remodeling in the hypertrophied heart.
Methods: Two weeks after banding the ascending aorta of male Sprague-Dawley
rats, a hemagglutinating virus of Japan-liposome complex with (H group) or without
(C group) human hepatocyte growth factor cDNA was transfected into the left
ventricle wall by direct injection. The hepatocyte growth factor, c-Met, and trans-
forming growth factor-1 mRNA levels in the left ventricle were then analyzed by
real-time quantitative reverse-transcriptase polymerase chain reaction.
Results: Two weeks after transfection, the expression of transforming growth
factor-1 mRNA was significantly attenuated in the H group compared with the C
group (P  .01). Myocardial collagen content after 4 weeks of banding was
significantly lower in the H group (5.0  0.6 mg/g tissue) than in the C group (7.4 
0.5 mg/g tissue, P  .01). Left ventricular diastolic function (E/A ratios quantified
by Doppler echocardiography) showed a significant increase in the H group (1.9 
0.1) compared with the C group (1.1  0.1, P  .01).
Conclusions: Our results demonstrated that gene transfection of hepatocyte growth
factor attenuated left ventricular diastolic dysfunction and cardiac fibrosis in asso-
ciation with a decrease in transforming growth factor-1 in the rat heart subjected
to pressure overload. Thus, the transfection of the hepatocyte growth factor gene
into the hypertrophied heart may be a strategy for the hypertrophied and failing heart
even for cardiac surgery.
Left ventricular hypertrophy (LVH) is most commonly induced by pressureoverload as a consequence of aortic valve stenosis in cardiovascular disease.The development of LVH seems to be an appropriate and beneficial adap-
tation to compensate for high left ventricular (LV) pressure. However, if the
increase in LV pressure persists, various alterations such as myocardial fibrosis and
depressed contractility occur, which can lead to heart failure. Such inappropriate
LVH has been associated with high perioperative morbidity and mortality.1
A number of growth factors, including insulin-like growth factor-I and trans-
forming growth factor (TGF)-1, have recently been reported to regulate cardio-
myocyte hypertrophy.2,3 TGF-1 has also been reported to regulate the expression
of collagen genes and extracellular matrix component synthesis in the heart and to
simultaneously block matrix degradation by decreasing the synthesis of proteases
and increasing the levels of protease inhibitors.4,5 Thus, TGF-1 plays a key role in
the development of cardiac fibrosis.
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CSPHepatocyte growth factor (HGF), which was originally
identified and cloned as a potent mitogen for hepatocytes,6,7
has been shown to play a significant role in mitogenic and
angiogenic activities for a wide variety of cells,8,9 and
moreover to inhibit fibrogenesis10,11 and apoptosis12,13 in
several organs. All of the biologic effects of HGF are
mediated by the c-Met receptor.14 We previously reported a
role of HGF in ischemia-reperfusion injury in the heart, and
c-Met expression was detected in the heart. Therefore, HGF
seems to be a significant growth factor for myocytes. How-
ever, no study has proven that HGF plays a role in the
hypertrophied heart.
TGF-1 suppresses the expression of HGF in several
types of cells, whereas an anti–TGF-1 antibody markedly
improves impaired HGF production. Therefore, TGF-1 is
a potent negative regulator of local HGF production in
various cells.15 Thus, it is reasonable to speculate that the
inhibition of TGF-1 production by enhancement of HGF
expression may attenuate the progression of fibrosis in the
hypertrophied heart.
In the present study, we first analyzed the expression of
endogenous HGF and the c-Met/HGF receptor compared
with the expression of TGF-1 in the hypertrophied heart.
We next determined whether overexpressing HGF in the
heart might attenuate the increase in TGF-1 expression
that plays an essential role in the progression of fibrosis
leading to heart failure.
Methods
Aortic Banding Model
LVH was induced in Sprague-Dawley rats (200 g in body weight)
by aortic banding.16 Rats were anesthetized with sodium pento-
barbital intraperitoneally and ventilated, and a right parasternal
thoracotomy was performed to expose the ascending aorta. A 5-0
polypropylene suture ligature was tied around the ascending aorta
against an 18-gauge needle, and the needle was then removed. Six
rats in each group were killed at 1, 2, 4, 7, 14, and 28 days after
surgery. In addition, unoperated rats were used as day 0 (preband-
ing) controls. All animals received proper care in compliance with
the institution’s guidelines.
Expression of Hepatocyte Growth Factor, c-Met, and
Transforming Growth Factor-1 mRNA in the
Hypertrophied Heart
Heart tissue was frozen immediately in liquid N2 for total RNA
isolation. mRNA transcripts were quantified by the dual-labeled
fluorogenic probe method for real-time reverse-transcriptase
polymerase chain reaction (RT-PCR), using a Prism 7700 ther-
mal cycler and sequence detector (Perkin-Elmer/ABI, Norwalk,
Conn). The RT-PCR primers and probes were the following: rat
HGF (GeneBank accession number D90102) sense, 5=-AA-
GAGTGGCATCAAGTGCCAG-3= and antisense, 5=-CTGGATT-
GCTTGTGAAACACC-3=, and 5=-(FAM)-TGATCCCCCATGAA-
CACAGCTTTTTG-(TAMRA)-3=; human HGF (GeneBank accession
number X16323) sense, 5=-TGCCCTATTTCTCGTTGTGAAG-3= and
antisense, 5=-TGTCGTGCAGTAAGAACCCAACT-3=, and 5=-(FAM)-
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(GeneBank accession number Y00671) sense, 5=-GTACGGT-
GTCTCCAGCATTTTT-3= and antisense, 5=-AGAGCACCAC-
CTGCATGAAG-3=, and 5=-(FAM)-ACCACGAGCACTGTT-
TCAATAGGACCC-(TAMRA)-3=; rat TGF-1 (GeneBank
accession number X52498) sense, 5=-GCTGAACCAAGGAGA-
CGGAATA-3= and antisense, 5=-GCCGTACACAGCAGTTCT-
TCTCT-3=, and 5=-(FAM)-CATGACATGAACCGACCCTTC-
CTGCT-(TAMRA)-3=; rat GAPDH, as a constitutive control
(GeneBank accession number X02231) sense, 5=-CCATCACT-
GCCACTCAGAAGAC-3= and antisense, 5=-TCATACTTGGC-
AGGTTTCTCCA-3=, and 5=-(FAM)-CGTGTTCCTACCCCC-
AATGTATCCGT-(TAMRA)-3=. The PCR data are reported as the
number of transcripts per number of rat GAPDH transcripts.
Transfection of the Human Hepatocyte Growth Factor
Gene Into the Heart
The human HGF cDNA was inserted into the Not I site of the
pUC-SR expression vector. The preparation of the liposome
complex with hemagglutinating virus of Japan (HVJ) has been
described.17 Two weeks after banding, rats were anesthetized
and ventilated, a left anterolateral thoracotomy was performed
to visualize the LV free wall, and approximately 0.5 mL of the
HVJ-liposome complex with human HGF cDNA, with 35 g of
cDNA (H group) or without human HGF cDNA (C group), was
transfected into the LV free wall by direct injection at several
points.
Enzyme-Linked Immunosorbent Assay for Rat and
Human Hepatocyte Growth Factor
The concentrations of rat HGF in the LV were determined by
enzyme-linked immunosorbent assay (ELISA) using an anti-rat
HGF monoclonal antibody (Institute of Immunology, Tokyo,
Japan). The concentrations of human HGF in the transfected LV
were also determined by ELISA using an anti-human HGF
monoclonal antibody (Tokusyumeneki Research Center, Tokyo,
Japan). The human HGF ELISA system specifically detects
human HGF but not rat HGF.18
Measurement of Left Ventricular Collagen Content
A portion of the LV free wall was homogenized in cold saline, and
the collagen content was measured by the quantitative dye-binding
method with the Sircol collagen assay kit (Biocolor Ltd, Belfast,
Ireland).
Echocardiography
Anesthetized and ventilated rats were assessed by a Sonos 5500
ultrasound system (Agilent Technologies, Palo Alto, Calif) with
a 12-MHz transducer. With the rat in the left lateral decubitus
position, the transducer was placed on the left hemithorax. Care
was taken to avoid excessive pressure, which can induce bra-
dycardia. With the parasternal short axis and/or long axis im-
aging plane as a guide, an LV M-mode tracing was obtained
close to the papillary muscle level, and pulse Doppler tracings
of the mitral inflow velocities were obtained in a modified
parasternal long-axis view at a sweep speed of 150 mm/s.19
Measurements of the ventricular septal thickness, LV internal dimen-
sion (LVID), and LV posterior wall thickness (LVPW) were made
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Pfrom 2-dimensional direct M-mode images of the LV in both
systole and diastole. Fractional shortening (FS), a measure of
systolic function, was calculated as FS (%)  [(LVIDdLVIDs)/
LVIDd]  100 where d indicates diastole and s indicates systole.
Doppler measurements of the peaks of the E (early diastolic
transmitral velocities) and A (late diastolic transmitral velocities)
waves were recorded as the average of 6 beats.
Statistical Analysis
All values were expressed as the mean  standard error of mean
(SEM). Statistical comparisons between groups were made by
analysis of variance, which was followed by an unpaired Student
t test when a significant difference was detected.
Results
Expression of Endogenous HGF and the c-Met/HGF
Receptor Compared With the Expression of TGF-1
in the Hypertrophied Heart
The level of rat HGF mRNA was significantly increased,
6-fold, after 2 days of banding (P  .05 vs prebanding) and
then declined gradually to 2 times the control level after 4
weeks of banding (Figure 1, A). The level of c-Met mRNA
was increased 2.6-fold after 2 days of banding (P  .05 vs
prebanding) and maintained at this level after 2 weeks of
banding (Figure 1, B). The level of TGF-1 mRNA was
increased 1.5-fold after 1 week of banding (P  .05 vs
prebanding) and increased gradually to 2.7 times the control
Figure 1. Results of quantitative reverse-transcripta
hypertrophied rat heart. The vertical axis denotes the
mRNA (B), and transforming growth factor (TGF)-1 mR
represent relative amplification (day 0 control values
accordingly) and are means  standard error of mean (
control.level after 4 weeks of banding (Figure 1, C).
The Journal of ThoraciThe expression of endogenously produced HGF pro-
tein in the rat LV was significantly increased until 4 days
after banding (55.2  4.0 ng/g tissue, P  .01 vs control;
11.9  1.4 ng/g tissue) and then gradually decreased.
In Vivo Hepatocyte Growth Factor Gene Transfection
Into the Hypertrophied Heart
Human HGF protein content in the transfected hearts was
measured with ELISA by using an anti-human HGF
monoclonal antibody. The level of human HGF in the H
group was 3.38  0.18 ng/g tissue at 1 day after transfection,
2.31 0.48 ng/g tissue at 4 days after transfection, and 0.22
 0.01 ng/g tissue at 7 days after transfection. In contrast,
human HGF protein was undetectable in the C group (Fig-
ure 2, A). Rat HGF protein content in the transfected hearts
was not measured by ELISA in our second study.
Moreover, to analyze the expression of the human
HGF transgene, total RNA was prepared from the trans-
fected LV free wall at 1, 2, 4, and 14 days after trans-
fection, and human HGF mRNA expression was then
analyzed by real-time RT-PCR using a primer set that
specifically detects human but not rat HGF mRNA. The
expression of human HGF mRNA was specifically de-
tected in the H group, even 14 days after transfection
(Figure 2, B ). In contrast, human HGF mRNA was un-
olymerase chain reaction (RT-PCR) analysis in the
nt of hepatocyte growth factor (HGF) mRNA (A), c-Met
C) normalized to the amount of GAPDH mRNA. Values
set at 1.0, and the remaining values were adjusted




SEM)detectable in the C group.
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Transfection on Cardiac Fibrosis in the Hypertrophied
Heart
After 2 weeks of transfection, the expression of TGF-1
mRNA was significantly lower in the H group (2.05  0.16
fold vs prebanding) than in the C group (2.69 0.25-fold vs
Figure 3. Expression of TGF-1 mRNA in the rat LV transfected
with (H group) and without (C group) human HGF, measured by
quantitative RT-PCR as described in “Methods.” The vertical axis
denotes the amount of TGF-1 mRNA normalized to that of GAPDH
mRNA. Values represent the relative amplification (the preband-
ing values were set at 1.0, and the remaining values were
adjusted accordingly) and are means  SEM for n  6 per group.
White star, P < .05 versus prebanding. Black star, P < .05 versus
C group. TGF, transforming growth factor.prebanding; P  .01) (Figure 3).
722 The Journal of Thoracic and Cardiovascular Surgery ● SeptThe myocardial collagen content of the LV free wall
after 4 weeks of banding was significantly lower in the H
group (5.0 0.6 mg/g tissue) than in the C group (7.4 0.5
mg/g tissue, P  .01) (Figure 4).
Effects of Hepatocyte Growth Factor Transfection on
Cardiac Function by Echocardiography
In the M-mode echocardiographic measurements, there
were no significant differences in the HR, LVID, ventricular
septal thickness, LVPW, and FS between the C and H
groups (Table 1). To assess the LV diastolic function, we
evaluated the peak early components of ventricular filling
(E velocity) and the E/A ratio by pulse Doppler echocardi-
ography. The C group showed a significant decrease in both
the E velocity and the E/A ratio compared with the pre-
banding control value (E velocity, C group: 53.9  7.8
cm/s, prebanding: 86.5  10.8 cm/s, P  .01; E/A ratio, C
group: 1.1  0.1, prebanding: 1.6  0.1, P  .01), whereas
the H group did not show a significant decrease. The H
group showed a significant increase in both the E velocity
and E/A ratio compared with the C group (E velocity, 85.3
 3.1 cm/s, P  .01 vs the C group; E/A ratio, 1.9  0.1,
P .01 vs the C group). There was no significant difference
in A velocity between the C group (50.1  2.9 cm/s) and the
H group (44.7  0.3 cm/s) (Figure 5).
Discussion
The present study demonstrated for the first time the differ-
ent patterns of HGF, c-Met, and TGF-1 mRNA expression
during the development of pressure-overload hypertrophy in
rat heart. After aortic banding, HGF and c-Met mRNA
increased significantly as early as 2 days after the operation,
and then decreased gradually toward the control levels,
whereas TGF-1 mRNA increased significantly as early as
7 days after the operation and continued to increase during
Figure 2. A, Expression of human HGF
protein in the rat left ventricle (LV)
transfected with human HGF. Human
HGF concentrations were measured by
enzyme-linked immunosorbent assay
(ELISA) as described in “Methods.” Val-
ues are means  SEM for n  6 per
group. B, Expression of human HGF
mRNA in the rat LV transfected with
human HGF, measured by quantitative
RT-PCR as described in “Methods.” The
vertical axis denotes the logarithm of
human HGF mRNA normalized to rat
GAPDH mRNA. Values are means 
SEM for n  6 per group. hHGF, human
hepatocyte growth factor.the development of pressure-overload–induced LVH.
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PMyocardial TGF-1 is thought to regulate cell differen-
tiation and proliferation, control protein synthesis, and reg-
ulate the degradation of extracellular matrix components,
and is correlated with myocardial hypertrophy.3,5 In vitro
studies demonstrated that TGF-1 expression increases col-
lagen gene expression and concomitantly reduces matrix
metalloproteinase (MMP) expression, and stimulates extra-
cellular matrix deposition from cultured cardiac fibro-
blasts.20 These correlative observations have led to the
suggestion that TGF-1 plays a pivotal role in cardiac
fibrosis. This coincided with our results that TGF-1
mRNA was persistently overexpressed during the develop-
ment of pressure-overload–induced LVH, and cardiac fibro-
sis progressed concomitantly, whereas HGF mRNA expres-
sion in the hypertrophied heart gradually decreased after its
initial induction by pressure overload.
It has been reported that TGF-1 is a strong negative
regulator of local HGF production, whereas HGF potently
suppresses the expression of TGF-1 in various organs.11,15
Although the mechanisms through which HGF inhibited
TGF-1 synthesis are not clear, HGF expression may down-
regulate TGF-1. Thus, a reciprocal balance may exist
between the expression of HGF and TGF-1.21 Previous
studies showed that the administration of human recombi-
nant HGF or the gene transfer of human HGF into rats with
hepatic fibrosis/cirrhosis induced by dimethylnitrosamine
attenuates the progression of the hepatic fibrosis/cirrhosis
by inhibiting TGF-1 expression.10 In our study, TGF-1
mRNA was persistently overexpressed during the develop-
ment of pressure-overload–induced LVH, and cardiac fibro-
sis progressed concomitantly, whereas HGF mRNA expres-
sion in the hypertrophied heart gradually decreased after its
initial induction by pressure overload. On the basis of these
findings, a potential therapy to prevent cardiac fibrosis may
be to supply growth factors that act as an antifibrotic factor,
such as HGF.
Moreover, HGF reduces the extracellular matrix accu-
mulation and promotes matrix degradation by increasing
MMP expression and reducing the levels of specific inhib-
itors, such as tissue inhibitors of MMP, in a coordinated
manner.22 A previous study demonstrated that HGF upregu-
lated Ets activity and Ets-1 protein in a myocardial infarc-
tion model.23 Ets-1 is a transcription factor that positively
regulates the expression of urokinase-type plasminogen ac-
tivator (uPA), MMP-1, MMP-3, and MMP-9.24 HGF in-
duces Ets-1 transcription,25 whereas TGF- attenuates the
transactivation activity of Ets-1 by inducing a protein that
interferes with Ets-1 binding to its DNA site.26 HGF seems
to have biologic activities that are the opposite of those of
TGF-1. Therefore, the antifibrotic actions of HGF depend
on inhibition of collagen synthesis through inhibition of
TGF-1 expression and degradation of collagen through
activation of MMP and uPA.
The Journal of ThoraciIn our second study, it was approximately a 20% increase
over basal endogenous HGF levels at the highest exogenous
HGF. We did not measure endogenous HGF at the time of
assay for human HGF. However, previous study has shown
that endogenous rat HGF was further increased by trans-
duction with exogenous human HGF in a rat liver cirrhosis
model through induction of Ets activity.27 Therefore, the
relatively small amount of exogenous HGF could have such
an impact on cardiac remodeling. We showed in our second
study that an increase in HGF production induced by trans-
fecting the HGF gene into rat hypertrophied heart signifi-
cantly inhibited TGF-1 expression and prevented cardiac
fibrosis. In the present study, we did not demonstrate that
antifibrotic actions of HGF depend on degradation of col-
lagen through upregulation of MMP and uPA. Although
little is known about how the overexpressed HGF inhibited
TGF-1 expression in the hypertrophied heart, an increase
in HGF expression in the LV may participate in the stimu-
lation of a matrix-degrading pathway and in the inhibition
of a TGF-1–regulated matrix-producing pathway. These
findings indicate that HGF in the hypertrophied heart may
play an important role in attenuating the progression of
cardiac remodeling.
We evaluated LV function by pulse Doppler echocar-
diographic interrogation of transvalvular flows. Transmi-
tral Doppler waveform analysis provides insight into the
temporal distribution of LV filling. Impaired LV relax-
ation and reduced ventricular compliance are reflected in
characteristic diastolic filling patterns. Transaortic Dopp-
ler waveform analysis can be used to estimate LV sys-
tolic function, but in this study it was difficult to assess
Figure 4. Changes in collagen content in the rat LV transfected
with (H group) and without (C group) human HGF, measured by a
quantitative dye-binding collagen assay as described in “Meth-
ods.” Values are means  SEM for n  6 per group. White star,
P < .01 versus prebanding. Black star, P < .01 versus C group.the transaortic flow because the ascending aortic banding
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ing. We found that the LV diastolic function was im-
paired, as indicated by the decrease in the peak early
components (E velocity) and the early to late diastolic
velocity ratio (E/A) of the ventricular filling during the
development of LVH and cardiac fibrosis. It is generally
believed that increased extracellular matrix content con-
tributes to diastolic stiffness and that this process ulti-
mately promotes ventricular dysfunction. The present
study demonstrated that the collagen content of the LV
free wall was markedly decreased by HGF overexpres-
sion, which therefore attenuated the significant decrease
in LV diastolic function compared with the untreated
heart.
We have shown that intracoronary infusion using the
HVJ-liposome method resulted in the efficient transduction
Figure 5. Efficacy of the gene transfection of HGF for L
and E/A ratio (B) in rat LV transfected with (H group) an
Doppler analysis as described in “Methods.” Values a
versus prebanding. Black star, P < .01 versus C group




HR (beats/min) 415 24 37
LVIDd (mm) 5.15 0.33 4.9
LVIDs (mm) 2.52 0.15 2.2
VSTd (mm) 1.41 0.10 1.9
LVPWd (mm) 1.63 0.09 2.4
FS (%) 51 2 6
HR, Heart rate; LVIDd, diastolic left ventricular internal dimension; LVIDs
thickness; LVPWd, diastolic left ventricular posterior wall thickness; FS, fra
prebanding.of a gene into the entire rat heart.28 In this study, the
724 The Journal of Thoracic and Cardiovascular Surgery ● SeptHVJ-liposome was transfected into the myocardium by
direct injection. The expression of human HGF mRNA in
the LV was detected by RT-PCR for 14 days after a single
injection of the HGF HVJ-liposome. The duration of HGF
overexpression induced using this method may be at least a
few weeks. Therefore, we consider this HVJ-liposome di-
rect injection method to be efficient, simple, and safe for in
vivo gene transfection into the myocardium. For clinical
applications in the field of cardiovascular surgery, this direct
injection of HVJ-liposome seems to a good method per-
formed during aortic valve replacement, which is the only
effective treatment for severe aortic valve stenosis with
concentric LV hypertrophy. With the HVJ-liposome
method the efficient period of gene transfection is limited.
Therefore, this method may be applied by means of inter-
mittent and repeated administration of HVJ-liposome using
stolic function. Changes in the E velocity, A velocity (A),
thout (C group) human HGF, measured by pulsed-wave










31 331 11 350  16
0.27 4.32 0.21 3.42 0.38
0.28 1.51 0.03 1.26 0.18
0.20 3.05 0.13* 2.67 0.31*
0.14 3.37 0.06* 3.14 0.41*
4 65  2 69  5*
olic left ventricular internal dimension; VSTd, diastolic ventricular septal














ctionaecho-guided direct or cardiac catheter injection.
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PConclusion
The overexpression of HGF significantly decreased the ex-
pression of TGF-1 and myocardial collagen content, and
attenuated the significant decrease in LV diastolic function
in the rat heart subjected to pressure overload. Overall, the
present study demonstrated that an increase in HGF in
association with a decrease in TGF-1 may attenuate car-
diac remodeling in the hypertrophied heart. Thus, transfec-
tion of the HGF gene into the hypertrophied heart may have
a role in the management of the hypertrophied and failing
heart.
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